Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1811 Combinations in HER2-Low Advanced Breast Cancer
NCT05792410Phase 2Unknown
- Sponsor
- Hengrui
- Start
- Apr 2023
- Primary completion
- Feb 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
Phase 2, open-label trial of trastuzumab rezetecan in breast cancer (3 arms), sponsored by Hengrui. Primary endpoints: Dose-Limiting Toxicity, Adverse Events up to 24 months and 2 more. Status: unknown.
02
Drugs
trastuzumab rezetecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05792410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05792410.